Key Points Alto Neuroscience (NYSE:ANRO) reported a net loss of $17.7 million (GAAP) in Q2 2025, with EPS of $(0.65) (GAAP). No revenue was reported, as the company remains in the clinical-stage ...

Net loss (GAAP) widened year over year for the six months ended Q2 2025, driven by sharply higher research and administrative expenses. Revenue (GAAP) fell 31.0% year-over-year for the six months ...